Fingolimod: A review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

Douglas R. Jeffery, Kottil W Rammohan, Kathleen Hawker, Edward Fox

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Fingolimod is an orally administered, first-in-class therapy for the treatment of relapsing forms of multiple sclerosis. Data from pivotal clinical trials show that fingolimod has a robust, significant effect on annualized relapse rates and MRI outcomes. Fingolimod has a novel, well-characterized mechanism of action. It acts through a specific set of receptors, sphingosine 1-phosphate receptors, present on the surface of a wide range of human cells and tissues, including neural cells, neurons and lymphocytes. Here we review the current literature to describe the mechanism of action of fingolimod in the context of its well-established clinical efficacy and safety profile. Understanding of the mechanisms behind any non-therapeutic effects of fingolimod facilitates their prediction and management in the clinical setting.

Original languageEnglish (US)
Pages (from-to)31-44
Number of pages14
JournalExpert Review of Neurotherapeutics
Volume16
Issue number1
DOIs
StatePublished - Jan 2 2016

Fingerprint

Multiple Sclerosis
Safety
Lysosphingolipid Receptors
Fingolimod Hydrochloride
Clinical Trials
Lymphocytes
Neurons
Recurrence
Therapeutics

Keywords

  • efficacy
  • Fingolimod
  • mechanism of action
  • multiple sclerosis
  • non-therapeutic effects
  • safety

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Fingolimod : A review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis. / Jeffery, Douglas R.; Rammohan, Kottil W; Hawker, Kathleen; Fox, Edward.

In: Expert Review of Neurotherapeutics, Vol. 16, No. 1, 02.01.2016, p. 31-44.

Research output: Contribution to journalArticle

@article{e80f1a58fddb4ff89e02f40d60ac190c,
title = "Fingolimod: A review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis",
abstract = "Fingolimod is an orally administered, first-in-class therapy for the treatment of relapsing forms of multiple sclerosis. Data from pivotal clinical trials show that fingolimod has a robust, significant effect on annualized relapse rates and MRI outcomes. Fingolimod has a novel, well-characterized mechanism of action. It acts through a specific set of receptors, sphingosine 1-phosphate receptors, present on the surface of a wide range of human cells and tissues, including neural cells, neurons and lymphocytes. Here we review the current literature to describe the mechanism of action of fingolimod in the context of its well-established clinical efficacy and safety profile. Understanding of the mechanisms behind any non-therapeutic effects of fingolimod facilitates their prediction and management in the clinical setting.",
keywords = "efficacy, Fingolimod, mechanism of action, multiple sclerosis, non-therapeutic effects, safety",
author = "Jeffery, {Douglas R.} and Rammohan, {Kottil W} and Kathleen Hawker and Edward Fox",
year = "2016",
month = "1",
day = "2",
doi = "10.1586/14737175.2016.1123094",
language = "English (US)",
volume = "16",
pages = "31--44",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Fingolimod

T2 - A review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

AU - Jeffery, Douglas R.

AU - Rammohan, Kottil W

AU - Hawker, Kathleen

AU - Fox, Edward

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Fingolimod is an orally administered, first-in-class therapy for the treatment of relapsing forms of multiple sclerosis. Data from pivotal clinical trials show that fingolimod has a robust, significant effect on annualized relapse rates and MRI outcomes. Fingolimod has a novel, well-characterized mechanism of action. It acts through a specific set of receptors, sphingosine 1-phosphate receptors, present on the surface of a wide range of human cells and tissues, including neural cells, neurons and lymphocytes. Here we review the current literature to describe the mechanism of action of fingolimod in the context of its well-established clinical efficacy and safety profile. Understanding of the mechanisms behind any non-therapeutic effects of fingolimod facilitates their prediction and management in the clinical setting.

AB - Fingolimod is an orally administered, first-in-class therapy for the treatment of relapsing forms of multiple sclerosis. Data from pivotal clinical trials show that fingolimod has a robust, significant effect on annualized relapse rates and MRI outcomes. Fingolimod has a novel, well-characterized mechanism of action. It acts through a specific set of receptors, sphingosine 1-phosphate receptors, present on the surface of a wide range of human cells and tissues, including neural cells, neurons and lymphocytes. Here we review the current literature to describe the mechanism of action of fingolimod in the context of its well-established clinical efficacy and safety profile. Understanding of the mechanisms behind any non-therapeutic effects of fingolimod facilitates their prediction and management in the clinical setting.

KW - efficacy

KW - Fingolimod

KW - mechanism of action

KW - multiple sclerosis

KW - non-therapeutic effects

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84955334334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955334334&partnerID=8YFLogxK

U2 - 10.1586/14737175.2016.1123094

DO - 10.1586/14737175.2016.1123094

M3 - Article

C2 - 26587577

AN - SCOPUS:84955334334

VL - 16

SP - 31

EP - 44

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -